{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:36:12Z","timestamp":1772768172777,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/mjt.0b013e31828bfb6e","type":"journal-article","created":{"date-parts":[[2013,7,11]],"date-time":"2013-07-11T12:26:34Z","timestamp":1373545594000},"page":"199-205","source":"Crossref","is-referenced-by-count":38,"title":["Transdermal Buprenorphine, Opioid Rotation to Sublingual Buprenorphine, and the Avoidance of Precipitated Withdrawal"],"prefix":"10.1097","volume":"22","author":[{"given":"Howard","family":"Kornfeld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Reetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210202","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1465-3362.2011.00291.x","article-title":"The prescription drug epidemic in the United States: a perfect storm.","volume":"30","author":"Maxwell","year":"2011","journal-title":"Drug Alcohol Rev"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/2012.jama.11248","article-title":"Petition targets painkiller marketing in effort to curb overdose deaths.","volume":"308","author":"Kuehn","year":"2012","journal-title":"JAMA"},{"key":"R3-6-20210202","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/archinternmed.2011.83","article-title":"Buprenorphine as a safety net for opioid treatment of nonmalignant pain.","volume":"171","author":"Kornfeld","year":"2011","journal-title":"Arch Intern Med"},{"key":"R4-6-20210202","first-page":"1269","article-title":". Canadian guideline for safe and effective use of opioids for chronic non-cancer pain.","volume":"57","author":"Kahn","year":"2011","journal-title":"Can Fam Physician"},{"key":"R6-6-20210202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain.","volume":"10","author":"Davis","year":"2012","journal-title":"J Support Oncol"},{"key":"R7-6-20210202","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1526-4637.2004.04044.x","article-title":"Good, P. Dear DEA letters.","volume":"5","author":"Heit","year":"2004","journal-title":"Pain Med"},{"key":"R8-6-20210202","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":". Current knowledge of buprenorphine and its unique pharmacological profile.","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Pract"},{"key":"R9-6-20210202","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/01.mjt.0000160935.62883.ff","article-title":"Sublingual buprenorphine is effective in the treatment of chronic pain syndrome.","volume":"12","author":"Malinoff","year":"2005","journal-title":"Am J Ther"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1749-6632.2011.06352.x","article-title":"The history of the development of buprenorphine as an addiction therapeutic.","volume":"1248","author":"Campbell","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"R14-6-20210202","first-page":"216","article-title":"Buprenorphine for pain management physicians: a dilemma or a therapeutic alternative Tech Reg Anesth Pain Manag.","volume":"9","author":"Myers","year":"2005","journal-title":""},{"key":"R16-6-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1521-0391.2012.00219.x","article-title":"Treatment of opioid dependence and cancer pain with sublingual buprenorphine: a case report.","volume":"21","author":"Park","year":"2012","journal-title":"Am J Addict"},{"key":"R17-6-20210202","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00520-005-0849-9","article-title":"Buprenorphine in cancer pain.","volume":"13","author":"Davis","year":"2005","journal-title":"Support Care Cancer"},{"key":"R18-6-20210202","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":". Buprenorphine induces ceiling in respiratory depression but not in analgesia.","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"issue":"Suppl 1","key":"R19-6-20210202","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1191\/0269216306pm1126oa","article-title":"Opioid-induced respiratory effects: new data on buprenorphine.","volume":"20","author":"Dahan","year":"2006","journal-title":"Palliat Med"},{"key":"R20-6-20210202","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":". Comparing overdose mortality associated with methadone and buprenorphine treatment.","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"R21-6-20210202","first-page":"85","article-title":"Fatal poisoning in methadone and buprenorphine treated patientsare there differences Pharmacopsychiatry.","volume":"39","author":"Soyka","year":"2006","journal-title":""},{"key":"R22-6-20210202","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00000542-200603000-00025","article-title":"Opioid-induced hyperalgesia: a qualitative systematic review.","volume":"104","author":"Angst","year":"2006","journal-title":"Anesthesiology"},{"key":"R23-6-20210202","doi-asserted-by":"crossref","first-page":"679","DOI":"10.36076\/ppj.2009\/12\/679","article-title":"Opioid induced hyperalgesia: clinical implications for the pain practitioner.","volume":"12","author":"Silverman","year":"2009","journal-title":"Pain Physician"},{"key":"R24-6-20210202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2007.04.006","article-title":". Sublingual buprenorphinenaloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.","volume":"90","author":"Rosado","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"R25-6-20210202","first-page":"628","article-title":". Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.","volume":"272","author":"Strain","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"R27-6-20210202","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/ADM.0b013e31821ee8fe","article-title":"Buprenorphine induction: a major barrier for physician adoption of office-based opioid dependence treatment.","volume":"5","author":"Gunderson","year":"2011","journal-title":"J Addict Med"},{"key":"R28-6-20210202","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1521-0391.2011.00159.x","article-title":". Transdermal buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms.","volume":"20","author":"Hess","year":"2011","journal-title":"Am J Addict"},{"key":"R29-6-20210202","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpainsymman.2007.01.006","article-title":". Switching from transdermal drugs: an observational N of 1 study of fentanyl and buprenorphine.","volume":"34","author":"Mercadante","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"R30-6-20210202","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1533-2500.2007.00119.x","article-title":". Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.","volume":"7","author":"Freye","year":"2007","journal-title":"Pain Pract"},{"key":"R31-6-20210202","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00213-008-1105-z","article-title":". Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation.","volume":"198","author":"Lanier","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R32-6-20210202","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/JPR.S6503","article-title":"Transdermal buprenorphinea critical appraisal of its role in pain management.","volume":"2","author":"Hans","year":"2009","journal-title":"J Pain Res"},{"key":"R33-6-20210202","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11606-008-0866-8","article-title":". Home buprenorphinenaloxone induction in primary care.","volume":"24","author":"Lee","year":"2009","journal-title":"J Gen Intern Med"},{"key":"R34-6-20210202","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.addbeh.2010.01.001","article-title":". Unobserved versus observed office buprenorphinenaloxone induction: a pilot randomized clinical trial.","volume":"35","author":"Gunderson","year":"2010","journal-title":"Addict Behav"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31828bfb6e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T12:10:08Z","timestamp":1646050208000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201505000-00006"}},"subtitle":["A Review of the Literature and Demonstration in Three Chronic Pain Patients Treated With Butrans"],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31828bfb6e","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}